Clinical trials: Age-Related Atrophy
Geographic Atrophy
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old.
- Trial name
- NCT06006585
- Testing
- BI 771716
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Atrophy, Geographic
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of GSK933776 in the treatment of geographic atrophy secondary to age-related macular degeneration.
- Trial name
- NCT01342926
- Testing
- GSK933776
- Where
- 41 sites in United States, Canada
- Volunteers
- 191 people
- Sponsor
- GlaxoSmithKline
Geographic Atrophy, Dry Age-Related Macular Degeneration
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration…
- Trial name
- NCT02686658
- Testing
- Avacincaptad Pegol
- Where
- 78 sites in United States, Croatia and 5 more
- Volunteers
- 286 people
- Sponsor
- IVERIC bio, Inc.
Geographic Atrophy
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
The objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant.
- Trial name
- PRIMAvera (NCT04676854)
- Testing
- PRIMA Bionic Vision System
- Where
- 21 sites in France, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Science Corporation
Age-Related Macular Degeneration, Geographic Atrophy
A Study of the SING IMT in an Israeli Cohort
The objective of this single center study is to determine the safety of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in a small sample of patients with moderate-severe central vision loss due…
- Trial name
- NCT05941273
- Testing
- smaller incision, new generation implantable miniature telescope (SING-IMT)
- Sponsor
- VisionCare, Inc.
Geographic Atrophy Secondary to Age-related Macular Degeneration
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who…
- Trial name
- GALE (NCT04770545)
- Testing
- PEGCETACOPLAN (APL-2)
- Where
- 175 sites in United States, Argentina and 13 more
- Volunteers
- 792 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Age-related Macular Degeneration
Global Atrophie Biomarker Evaluation Study (GABiE)
To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.
- Trial name
- GABiE (NCT03935126)
- Testing
- Diagnostics
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
Retinitis Pigmentosa, Macula Off
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.
- Conditions
- Retinitis Pigmentosa, Macula Off, Primary Open Angle Glaucoma, Hereditary Macular Degeneration
- Trial name
- NCT00804102
- Testing
- Transcorneal Electrical Stimulation, DTL-electrode attached without energy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okuvision GmbH
Geographic Atrophy
A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.
- Trial name
- NCT01603043
- Testing
- Al-78898A
- Volunteers
- 10 people
- Sponsor
- Alcon Research
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy…
- Trial name
- CHROMA (NCT02247479)
- Testing
- Lampalizumab
- Where
- 145 sites in United States, Argentina and 17 more
- Volunteers
- 906 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD).
- Trial name
- ArMaDa (NCT06018558)
- Testing
- OCU410
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ocugen
Age-Related Maculopathy
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
- Trial name
- NCT01577381
- Testing
- RN6G
- Where
- 83 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Dry Age-related Macular Degeneration
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
- Trial name
- NCT07770828
- Testing
- OCU410
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Ocugen
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary…
- Trial name
- VISION (NCT06765980)
- Testing
- VV-14295
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 62 people
- Sponsor
- Kriya Therapeutics, Inc.
Geographic Atrophy
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96…
- Trial name
- NCT02745119
- Testing
- Lampalizumab
- Where
- 208 sites in United States, Australia and 17 more
- Volunteers
- 994 people
- Sponsor
- Hoffmann-La Roche
Dry Age-related Macular Degeneration
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over age 60. AMD is classified as wet and dry.
- Trial name
- NCT03144999
- Testing
- AAVCAGsCD59
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Trial name
- NCT07441642
- Testing
- FWY003
- Where
- 59 sites in United States, Argentina and 16 more
- Volunteers
- 272 people
- Sponsor
- Novartis Pharmaceuticals
Sarcopenia, Gait Disorders in Old Age
A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)
The main objective of the study is to evaluate the effect of two daily doses of BIO101 versus placebo on mobility function as measured by gait speed using the 400MW test.
- Conditions
- Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
- Trial name
- SARA-INT (NCT03452488)
- Testing
- BIO101
- Where
- 22 sites in United States, Belgium
- Volunteers
- 233 people
- Sponsor
- Biophytis
Dry Age-related Macular Degeneration, Geographic Atrophy
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
- Trial name
- NCT01002950
- Testing
- ACU-4429
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- Kubota Vision Inc.
Geographic Atrophy (GA)
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to…
- Trial name
- VIENNA (NCT07230834)
- Testing
- Pozelimab
- Where
- 9 sites in United States, Georgia and 2 more
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals